Introducing Reltio Enterprise 360 Site Intelligence for Fast, Efficient Clinical Trials
Fully Enroll Research Studies.
Every Time. All the Time.
Beat the Odds. Be Better with Reltio Enterprise 360 Site Intelligence.
The path to commercialization for every FDA approved drug and cleared medical device in the United States began with a Clinical Trial. Recruitment of Study Sites, generally Healthcare Organizations (HCO), and Principal Investigators (PI), often healthcare providers (HCP), are fundamental, but often vexing, first steps in starting a clinical trial. Failure to recruit the best Study Sites and PIs for a protocol is second only to inadequate patient recruitment and retention for the failure of Clinical Trials.
Research published in Contemporary Clinical Trials (2018) reports that 86 percent of clinical trials do not reach recruitment targets within specified time periods. Another 19 percent of registered trials were closed or terminated early because they could not accrue enough participants. The authors note that, “Failures in meeting recruitment goals have important scientific, financial, ethical, and policy implications.”
“Although regulatory approval time for new drugs in the United States is shortening, the time needed, on average, to complete clinical development of those drugs is lengthening by a greater amount, leading to longer times to develop and bring new drugs to market in this country.”
- Tufts Center for the Study of Drug Development, July/August Tufts CSDD Impact Report, 2020
Data-Driven Insights for Precise Recruitment and High-Quality Research Studies
Reltio Enterprise 360 Site Intelligence is a cloud-native service that enables Pharma R&D Teams and Contract Research Organizations (CRO) to centralize detailed data about Study Sites and PIs, including past performance, ratings, and competitive information, from multiple sources. Making decisions based on Unified, Reliable, Real-Time data can mean the difference between success and failure, profit and loss.
Access, decentralization, and trial modalities became issues as COVID-19 took Study Sites and PIs off-line, and study subjects - patients - quarantined. Clinical trials moved online in step with many other aspects of our business and personal lives, enabled by wearable technology and remote monitoring. Looking beyond the usual geographic areas and including under-served populations became critical factors that determined whether a study launched, was put on hold, or was canceled.
Reltio Site Intelligence enables CROs and Clinical Trial Teams to:
- Define the key criteria for site selection, based on each new Protocol, leveraging experience and results.
- Search all available HCOs/Sites and HCPs/Investigators based on the most up-to-date information.
- Evaluate and rate Study Sites and PIs based on quantitative metrics and qualitative criteria, such as adverse events and alignment with intervention / treatment areas, using Machine Learning technology.
- Manage consent, contracting and collaboration workflows
Identify
the best Sites for a
Clinical Study
Involve
the best Investigators
for a Clinical Study
Optimize
study startup and
Site Initiation
Ensure
patient enrollment
Reduce
issues and delays during
Study Execution
Automate
collaborations within team
and reduce manual effort
One Stop
platform to manage
Site Selection
Reltio Enterprise 360 Site Intelligence is the single platform for:
- Third-Party Industry and Reference Data
- Operational and Analytical Data
- HCO Data
- HCP Data
- Study and Study Sites Data
Reltio’s first customers were life sciences and pharmaceutical companies. In fact, 9 of the Top 10 Pharma companies use Reltio Connected Data Platform for drug Research & Development, commercialization, direct-to-consumer marketing, and distribution management (sales & marketing). We understand the data you need to be successful. And we have been delivering it to our customers on a cloud-native, multi-domain master data management (MDM) software as a service platform for nearly 7 years.
Connected Graph technology is unique to Reltio Enterprise 360 Site Intelligence. PIs, study sites, HCOs, and HCPs are often connected in many-to-many relationships. Graph reveals valuable insights that traditional databases cannot. Graph technology can quickly identify content preferences, influence in a disease area, prescribed products, and clinical trial participation. The graph helps model inter-relationships and dynamic hierarchical information for an at-a-glance view.
AI provides insight into key considerations for Clinical Trials. These include Study Site and PI performance on past studies, relationships with competitors, areas of expertise, site logistics, and other important data.
Increasing the potential pool of Study Sites, PIs, and Patients - and conducting Research Studies in ways that optimize enrollment and management - is the new normal... and mandatory.
Reltio Enterprise 360 Site Intelligence Reference Architecture
With Reltio Enterprise 360 Site Intelligence, CROs, Pharma Clinical Trials and R&D teams, and other Research Study Professionals can:
- Define Metrics used to rank HCOs/Sites and HCPs/Investigators.
- Provide personalized weightages to performance metrics.
- View Ranking of HCOs/Study Sites and HCPs/PIs based on defined performance metrics and weightings.
- Identify and rectify data quality problems and have full auditability through a built-in dashboard for data governance and stewardship.
Who should use Reltio Enterprise 360 Site Intelligence?
- Clinical Operations
- R&D Strategy
- Clinical Research Associate (CRAs)
- Clinical Analytics & Reporting
- Clinical IT
- Clinical and Medical Affairs (IT)
- Clinical Development
- Regulatory Science
- Global Medicines Development
- Clinical Trial Safety Management
- Product Owner, Patient, Site Selection & Recruitment Solutions
- Site Intelligence Project Manager
- Head of Site Startup
- Feasibility and Site Selection
- Strategic Site Intelligence Specialist
- Site Intelligence Analyst
- Clinical Information Science Director
- Clinical Systems
- Clinical Systems & Performance Analytics
- Health Economics and Outcomes Research
